LH Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Growth And Margin ExpansionRecent growth is broad enough to support durable earnings improvement: revenue increased, operating margin expanded, and adjusted EPS advanced. If maintained, this combination gives Labcorp more capacity to invest in diagnostics, biopharma services, technology and shareholder returns over the next several quarters.
Biopharma BacklogThe large Biopharma Laboratory Services backlog provides meaningful forward revenue visibility, while book-to-bill above one indicates demand is replenishing delivered work. This supports continued segment growth and helps underpin more predictable utilization and earnings over the coming quarters.
Innovation And PartnershipsNew testing offerings, reimbursement progress and expanded health-system connectivity broaden Labcorp’s commercial reach across consumer, clinical and personalized-care markets. These initiatives can support specialty mix, improve access to testing and create additional durable growth channels beyond routine diagnostics.
Bears Say
Medicare Reimbursement RiskThe preliminary CMS fee schedule creates a material multi-year reimbursement risk for the Diagnostics business. Lower Medicare payment rates could pressure pricing and margins through 2029, while the final impact remains uncertain and may require Labcorp to rely more heavily on volume, mix and efficiency improvements.
Meaningful LeverageAlthough leverage is described as manageable and has improved from 2024, the absolute debt balance remains substantial relative to equity. This reduces financial flexibility, keeps interest and refinancing obligations important, and could constrain acquisitions, investment or shareholder returns if operating conditions weaken.
Margins Below PeakImproved profitability has not restored Labcorp’s earlier margin profile, indicating that earnings quality remains below its prior peak. Sustained margin compression leaves less buffer against reimbursement pressure and operating costs, and makes future earnings growth more dependent on execution and mix improvement.
Labcorp Holdings News
LH FAQ
What was Labcorp Holdings’s price range in the past 12 months?
Currently, no data Available
What is Labcorp Holdings’s market cap?
Labcorp Holdings’s market cap is CHF20.78B.
When is Labcorp Holdings’s upcoming earnings report date?
Labcorp Holdings’s upcoming earnings report date is Oct 28, 2026 which is in 26 days.
How were Labcorp Holdings’s earnings last quarter?
Labcorp Holdings released its earnings results on Jul 30, 2026. The company reported CHF4.174 earnings per share for the quarter, beating the consensus estimate of CHF3.997 by CHF0.176.
Is Labcorp Holdings overvalued?
According to Wall Street analysts Labcorp Holdings’s price is currently Undervalued.
Does Labcorp Holdings pay dividends?
Labcorp Holdings does not currently pay dividends.
What is Labcorp Holdings’s EPS estimate?
Labcorp Holdings’s EPS estimate is 3.89.
How many shares outstanding does Labcorp Holdings have?
Currently, no data Available
What happened to Labcorp Holdings’s price movement after its last earnings report?
Labcorp Holdings reported an EPS of CHF4.174 in its last earnings report, beating expectations of CHF3.997. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Labcorp Holdings?
Currently, no hedge funds are holding shares in CH:LH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF284.51 (― Upside)
CHF284.51 (― Upside)
Blogger Sentiment
Neutral
CH:LH Sentiment 60%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth CHF598.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Labcorp Holdings
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
LH Company Deck
LH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and financial quarter: revenue growth, margin expansion, double-digit adjusted EPS growth, raised guidance, robust BLS backlog and book-to-bill, and multiple product/partnership launches. Headwinds highlighted were a meaningful quarter-over-quarter drop in free cash flow (timing and capex), a modest ACA-related volume headwind (~30 bps), prior and improving Early Development softness, higher patient-pay mix, and elevated absolute debt with relatively low cash on hand. On balance the positives around revenue, margins, guidance increases, product/market progress, and capital returns materially outweigh the cited challenges.View all CH:LH earnings summariesLH Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations
